New Haven, Conn. — Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this technology — which allows scientists to use a “guide” RNA to modify DNA sequences and evaluate the effects — is able to target, delete, replace, or modify only single gene sequences with a single guide RNA and has limited ability to assess multiple genetic changes simultaneously.

Now, however, Yale scientists have developed a series of sophisticated mouse models using CRISPR (“clustered regularly interspaced short palindromic repeats”) technology that allows them to simultaneously assess genetic interactions on a host of immunological responses to multiple diseases, including cancer.

The findings were published March 20 in the journal Nature Biomedical Engineering.

Women with polycystic ovary syndrome (PCOS) find it harder to get pregnant, have more frequent miscarriages and have a higher risk of developing endometrial cancer. Now, in a new study published in Nature Medicine, Swedish researchers have shown that the uterine lining of these women differs in terms of both the composition of individual cells and gene expression. The results open the door to new drug treatments.

The new approach establishes an opportunity to harness the success of immunotherapies that revolutionized the treatment of childhood leukemias for childhood brain cancers.